This shared resource supports 2 functions: patient sample repository and specialized flow cytometry. The repository functions of the core include the acquisition of appropriate patient samples, isolation and cryopreservation of mononuclear cells, separation and storage of plasma or serum, maintenance of a database annotating patient samples and distribution of samples to program investigators. We will safeguard patient privacy by ensuring that all samples are de-identified and are assigned coded unique identifying numbers. We will also verify compliance with our internal regulatory policies which stipulate that samples may be obtained and studied only from patients who have signed an IRB approved informed consent document. The flow cytometry functions of the core include multiparameter analysis of heterogeneous samples and high-speed cell sorting to obtain highly purified populations of defined progenitor populations.
The specific aims of this core are listed below: 1. To ensure the maintenance of patient privacy and to verify that informed consent has been obtained for acquisition and study of all samples. 2. To ensure the acquisition of appropriate samples as designated in clinical research protocols carried out by program investigators. 3. To isolate and cryopreserve mononuclear cells and plasma or serum components from patient samples for subsequent study by program investigators. 4. To maintain an annotated database containing pathologic, cytogenetic and molecular information for clinical samples obtained from patients with myeloid leukemias. 5. To ensure that samples are distributed in a timely and equitable fashion to laboratory investigators for experiments proposed in this application. 6. To provide specialized multi-parameter analysis and high-speed cell sorting to obtain highly purified populations for functional and genetic analysis

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-15
Application #
8377892
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
2014-03-30
Budget Start
2012-04-01
Budget End
2013-03-30
Support Year
15
Fiscal Year
2012
Total Cost
$178,441
Indirect Cost
$58,878
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Townsend, Elizabeth C; Murakami, Mark A; Christodoulou, Alexandra et al. (2016) The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 29:574-86
Arreba-Tutusaus, P; Mack, T S; Bullinger, L et al. (2016) Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia 30:1220-5
Tanaka, Minoru; Roberts, Justin M; Seo, Hyuk-Soo et al. (2016) Design and characterization of bivalent BET inhibitors. Nat Chem Biol 12:1089-1096
Wu, H; Hu, C; Wang, A et al. (2016) Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 30:173-81
Wu, H; Hu, C; Wang, A et al. (2016) Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 30:754-7
Puram, Rishi V; Kowalczyk, Monika S; de Boer, Carl G et al. (2016) Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell 165:303-16
Brien, Gerard L; Valerio, Daria G; Armstrong, Scott A (2016) Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell 29:464-76
Zhu, Nan; Chen, Mo; Eng, Rowena et al. (2016) MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest 126:997-1011
Schneider, Rebekka K; Schenone, Monica; Ferreira, Monica Ventura et al. (2016) Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med 22:288-97
Hatcher, John M; Weisberg, Ellen; Sim, Taebo et al. (2016) Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett 7:476-81

Showing the most recent 10 out of 280 publications